Human Genome Sciences Initiates Second Randomized Phase 2 Trial of HGS-ETR1 in Combination With Ch...(ment ofcancer in early 2008. Preclinical...)

Date:12/20/2007

ment of cancer in early 2008. Preclinical studies have demonstrated that AEG40826 and the HGS TRAIL receptor antibodies exhibit dramatic synergistic activity in a broad range of cancers. HGS plans to develop the TRAIL receptor antibodies and IAP inhibitors in combination with one another and in combination with other therapies.

"The TRAIL-mediated apoptosis pathway is an exciting area of cancer research, and agonistic antibodies to this target offer great promise to patients with a wide variety of cancers. HGS-ETR1 is the most advanced of these antibodies, now with two randomized Phase 2 chemotherapy combination trials ongoing," said David C. Stump, M.D., Executive Vice President, Research and Development, HGS. "In addition, with the licensing and collaboration agreement we announced today, we have strengthened our oncology franchise by adding small-molecule drugs known as IAP inhibitors, which also enhance apoptosis in cancer cells. We look forward to developing our TRAIL receptor antibodies and IAP inhibitors in combination with one another and in combination with other therapeutic agents."

About the Phase 2 Trial Design

This randomized, multi-center, open-label Phase 2 study is designed to evaluate the efficacy and safety of HGS-ETR1 in combination with carboplatin and paclitaxel as first-line therapy in the treatment of advanced non-small cell lung cancer (Stage IIIB or IV). Approximately 105 patients will be randomly assigned among three treatment groups and treated with either the two-agent combination of carboplatin and paclitaxel or the three-agent combination of carboplatin, paclitaxel and HGS-ETR1 at either 10 mg/kg or 30 mg/kg.

About Previous Results in Non-Small Cell Lung Cancer

The results of in vitro and in vivo preclinical studies demonstrate that: (1) TRAIL receptor 1 is differentially expressed on non-small cell lung cancer (NSCLC) cells compared with normal cells; (2) HGS-ETR1 specifically binds TRAIL receptor 1 a
'/>"/>

SOURCE Human Genome Sciences, Inc. Copyright©2007 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6
Related biology technology :

1. Expiry of Hart-Scott-Rodino Waiting Period for JUVISTA(R) (Human TGF BETA 3)
2. New Initiative Has Shocking Effect: Thousands of Missourians with Abnormal Chromosome Structures Are Not Human
3. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
4. Human Genome Sciences Announces $40 Million Milestone Payment Related to Albuferon(R) Development
5. Novocell Announces Discovery Linking Key Cancer Cell Signaling Pathways With Proliferation and Self-Renewal of Human Embryonic Stem Cells
6. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Thomas Weisel Partners Conference
7. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at BioCentury-Thomson Financial Investment Conference
8. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Bear Stearns Conference
9. Human Pheromone Sciences Enters Into Agreement to Reposition and Promote its Natural Attraction(R) Brand
10. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Merrill Lynch Conference
11. Premier Research Appoints Global Head of Human Resources